In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ohm Laboratories

Division of Sun Pharmaceutical Industries Ltd.

Latest From Ohm Laboratories

Ranbaxy Seeks Nexium Generic API Sources In Face Of Nearby Launch

Ranbaxy Laboratories is discussing with at least two companies with U.S. FDA-approved factories to supply it with the active pharmaceutical ingredients it relies on for its generic of AstraZeneca's Nexium (esomeprazole) for treating heartburn.

BioPharmaceutical India

Ranbaxy Said To Have Partner For API Of Novartis Drug Diovan

Ranbaxy Laboratories reportedly has filed formulation details with U.S. FDA for valsartan, the API of Novartis’ hypertension drug Diovan based upon a partnership with another multinational drug maker.

BioPharmaceutical India

Another FDA 483 At Ranbaxy’s Toansa API Site May Hold Up Key Launches

Ranbaxy’s compliance woes keep coming with the latest news that its crucial API facility was cited as a follow-up to FDA inspections. The fate of several of its key drugs hangs in the balance.

BioPharmaceutical India

Ranbaxy Ends Four-Year U.S. Export Hiatus With Generic Of Pfizer’s Lipitor

Ranbaxy Laboratories resumed exports of its generic of Pfizer’s cholesterol drug Lipitor to the U.S. in the wake of a lift of the four-year ban imposed by U.S. FDA at two of its India production facilities.

BioPharmaceutical India
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register